1. Home
  2. MTEK vs CALC Comparison

MTEK vs CALC Comparison

Compare MTEK & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maris-Tech Ltd.

MTEK

Maris-Tech Ltd.

HOLD

Current Price

$1.24

Market Cap

11.7M

Sector

N/A

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.78

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTEK
CALC
Founded
2008
2011
Country
Israel
United States
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MTEK
CALC
Price
$1.24
$0.78
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
359.1K
762.7K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.09
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.46
52 Week High
$4.27
$7.20

Technical Indicators

Market Signals
Indicator
MTEK
CALC
Relative Strength Index (RSI) 48.51 50.74
Support Level $1.08 $0.52
Resistance Level $1.41 $0.93
Average True Range (ATR) 0.11 0.11
MACD -0.01 -0.03
Stochastic Oscillator 64.13 47.81

Price Performance

Historical Comparison
MTEK
CALC

About MTEK Maris-Tech Ltd.

Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: